Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101
Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with Rare Epilepsies
Questcorp Mining and Riverside Resources Report High-Grade Gold, Silver and Base Metal Results and Advance Toward Fully Funded Phase 2 Drill Program at La Union, Sonora
Alvopetro Announces April Sales Volumes, Quarterly Natural Gas Pricing Update and Details for Q1 2026 Earnings Call
